Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET
Company Participants
Diane Weiser - Senior Vice President, Corporate Communications & Investor Relations
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, Research & Development
Andrew Callos - Executive Vice President & Chief Commercial Officer
Stuart Kupfer - Senior Vice President & Chief Medical Officer
Robert Wong - Vice President & Chief Accounting Officer
Ching Jaw - Senior Vice President & Chief Financial Officer
Conference Call Participants
Carter Gould - Barclays
Yasmeen Rahimi - Piper Sandler
Joe Pantginis - H.C. Wainwright.
Jason Butler - JMP Securities
Jeff Hung - Morgan Stanley
Ash Verma - UBS
Salim Syed - Mizuho
Justin Kim - Oppenheimer
Dane Leone - Raymond James
Charles Duncan - Cantor Fitzgerald
Rohit Bhasin - Needham & Company
Operator
Good afternoon, and welcome, ladies and gentlemen to Cytokinetics' Third Quarter 2022 Conference Call. At this time, I would like to inform you that this call is being recorded. And that all participants are in a listen-only mode. [Operator Instructions].
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with a brief overview of the quarter and recent developments; Fady Malik, EVP of R&D, will provide updates related to omecamtiv mecarbil and aficamten; Andrew Callos, EVP and Chief Commercial Officer, will review commercialization planning activities for omecamtiv mecarbil and our specialty cardiology franchise strategy related to aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will provide an update on reldesemtiv; Robert Wong, VP and Chief Accounting Officer will provide a financial overview of the past quarter; and Ching Jaw, SVP and Chief Financial Officer, will discuss our financial outlook and corporate development. Then finally, Robert Blum will provide closing comments and review expected upcoming key milestones.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings including our current report regarding our third quarter 2022 financial results filed on Form 8-K today. We undertake no obligation to update any forward-looking statements after this call.